Summary & Overview
HCPCS J0210: Injection, Methyldopate HCl, up to 250 mg
HCPCS Level II code J0210 represents an injectable dose of methyldopate hydrochloride (up to 250 mg), a vasoactive agent used for acute blood pressure support. Nationally, this code matters for hospital and emergency care billing where parenteral antihypotensive therapy is provided and for payers managing coverage of acute inpatient and emergency therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for methyldopate administration, the typical sites of service where J0210 appears, and the payer landscape relevant to this HCPCS Level II code. The publication outlines common billing modifiers associated with injectable therapeutics, typical billing considerations for acute-care injectable agents, and benchmarks where available. It also highlights policy and coverage topics that often affect reimbursement for parenteral antihypotensive medications, including prior authorization and medical necessity documentation practices.
This summary is designed to give clinicians, billing professionals, and policy analysts a concise briefing on what J0210 covers, who commonly pays for services billed with this code, and the key areas to examine further when assessing coverage and claims for methyldopate injections.
Billing Code Overview
HCPCS Level II code J0210 denotes injection, methyldopate HCl, up to 250 mg. This code describes a single-dose injectable formulation of methyldopate hydrochloride, an antihypotensive agent used in acute care settings when rapid blood pressure support is required.
Service Type: Therapeutic injection/infusion
Typical Site of Service: Hospital inpatient, emergency department, or other acute care setting
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is a hospitalized adult with acute, severe hypertension or hypertensive emergency who cannot take oral medications due to altered mental status, vomiting, or NPO status. After assessment by the inpatient medicine or critical care team, intravenous vasopressor support and parenteral antihypertensive therapy are considered. Methyldopate (methyldopa HCl) injection J0210 may be administered by a registered nurse or advanced practice provider in an emergency department, inpatient ward, or intensive care unit when rapid blood pressure control is required and enteral routes are unavailable. The clinical workflow involves: initial vital signs and neurologic assessment; order entry with indication and dose; pharmacy verification and preparation of J0210; bedside administration with appropriate monitoring of blood pressure, heart rate, and level of consciousness; documentation of dose, route, time, and patient response; and adjustment of ongoing antihypertensive regimen or transition to oral therapy when clinically appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier reporting requirements | Used when no other specific modifier applies to the service |